Oral Semaglutide (Wegovy® Pill): 7mg
Weight managementDescription
Fda-approved oral semaglutide (wegovy® pill) — the first oral glp-1 receptor agonist approved for chronic weight management in the united states (january 2026). uses a snac absorption enhancer to enable gastric mucosal absorption. oasis 2 clinical trial: 15.1% mean body weight reduction at 68 weeks. dose-escalation protocol: 7mg once daily for 4 weeks, then 14mg once daily. taken 30 minutes before the first food, drink, or other oral medication of the day with no more than 4 oz plain water. bioavailability approximately 1% compared to subcutaneous injection. over 3 million us prescriptions as of mid-2026. this is an fda-approved prescription pharmaceutical — not a research peptide. compounded oral semaglutide is not authorized under any current fda pathway.
Specifications
| Amount in Vial | 7mg (30 tablets) |
|---|---|
| BAC Water | n/a |
| Amount per Unit | 7mg per tablet |
| Recommended Dose | 7mg to 14mg (1 to 2 tablets) |
| Frequency | Daily |
| Injection Type | Oral tablets |
| Timing | 30 minutes before first food or drink of the day, with 4 oz plain water only |
Dose Calculator
Based on 7mg per tablet (100-unit insulin syringe)
Quick Reference
Reconstitution
Vial size: 7mg (30 tablets)
Add BAC water: n/a
Concentration: 7mg per tablet
For research and educational use only.
This page provides research dosing information only. Not intended as medical advice. Consult a qualified professional before any use.